Evidence map›Paper›PMID 28094402›Full record

ArticleNanoscale2017

Mesoporous carbon nanoshells for high hydrophobic drug loading, multimodal optical imaging, controlled drug release, and synergistic therapy.

Hui Wang, Kui Wang, Qingxin Mu, Zachary R Stephen, Yanyan Yu, Shuiqin Zhou, Miqin Zhang

Abstract read
In one paragraph

Article in Nanoscale, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Iron oxide-carbon core-shell nanoparticles for dual-modal imaging-guided photothermal therapy.Journal of controlled release : official journal of the Controlled Release Society · 2018
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hui Wang *Department of Materials Science and Engineering, University of Washington, Seattle, Washington 98195, United States.
Kui Wang *Department of Materials Science and Engineering, University of Washington, Seattle, Washington 98195, United States.
Qingxin MuDepartment of Materials Science and Engineering, University of Washington, Seattle, Washington 98195, United States.
Zachary R StephenDepartment of Materials Science and Engineering, University of Washington, Seattle, Washington 98195, United States.
Yanyan YuDepartment of Chemistry of The College of Staten Island and The Graduate Center, The City University of New York, Staten Island, New York 10314, United States.
Shuiqin ZhouDepartment of Chemistry of The College of Staten Island and The Graduate Center, The City University of New York, Staten Island, New York 10314, United States.
Miqin ZhangDepartment of Materials Science and Engineering, University of Washington, Seattle, Washington 98195, United States.

Funding

Multifunctional nanoparticles to improve treatment of human glioblastomaR01CA161953 · NCI · UNIVERSITY OF WASHINGTON · PI ZHANG, MIQIN · 2013 to 2017
$1.7M
NCI NIH HHS R01 CA161953
6 · The paper itself

Abstract

Loading and controlled release of sufficient hydrophobic drugs to tumor cells has been the bottleneck in chemotherapy for decades. Herein we report the development of a fluorescent and mesoporous carbon nanoshell (FMP-CNS) that exhibits a loading capacity for the hydrophobic drug paclitaxel (PTX) as high as ∼80 wt% and releases the drug in a controllable fashion under NIR irradiation (825 nm) at an intensity of 1.5 W cm

Indexed as

CarbonDrug LiberationNanoshellsAnimalsDrug CarriersGlioblastomaHydrophobic and Hydrophilic InteractionsMiceMice, NudePaclitaxelRatsXenograft Model Antitumor AssaysCarbonDrug CarriersPaclitaxel

Identifiers

PMID28094402
PMCPMC5334464

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.